Application/Control 10/731,074	Reexan	Applicant(s)/Patent Under Reexamination ELOKDAH ET AL.		
Examiner	Art Unit			
Michael P Barker	1626	Page 1 of 5		

## **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	Α	US-6,232,327	05-2001	Nickel et al.	514/337
*	B.	US-4,851,406	07-1989	Mertens et al.	514/217.04
	С	US-			
	D	US-		•	
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	I	US-			
	J	US-			
	К	US-			
	L	US-		·	
	М	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
:	N	WO 3068742 A1	08-2003	World Intellect	DELUCA et al.	C07D209/20
	0	WO 9626207 A1	08-1996	World Intellect	OHARA et al.	C07D417/06
	Р					
	Q					
	R					
	S					
	Т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ashitani J. Mukae H. Arimura Y. Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. [Journal Article] Internal Medicine. 41(3):181-5, 2002 Mar.
	٧	Razavi MK. Wong H. Kee ST. Sze DY. Semba CP. Dake MD. Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. [Clinical Trial. Journal Article] J. of Endovascular Therapy: Official Journal of the International Society of Endovascular Therapy: Official Journal of the International Society of Endovascular Specialists. 9(5): 593-8. 2002 Oct.
	W	Rocha-Singh KJ. Trokey J. Combined glycoprotein Ilb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.[Clinical Trial. Journal Article] Catheterization & Cardiovascular Interventions. 55(4):457-60, 2002 Apr.
لا	х	Albers GW. Advances in intravenous thrombolytic therapy for treatment of acute stroke. [Review] [37 refs] [Journal Article. Review] Neurology. 57(5 Suppl 2):S77-81, 2001.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

#### Applicant(s)/Patent Under Reexamination 10/731,074 ELOKDAH ET AL. Notice of References Cited Art Unit Examiner Page 2 of 5 1626 Michael P. Barker

Application/Control No.

#### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
:	G	US-			
	Н	US-			
	ı	US-			
	J	US-			
	κ	US-			*
	L	US-			
	М	US-			

## FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
4.5	U	Hamano K. Iwano M. Akai Y. Sato H. Kubo A. Nishitani Y. Uyama H. Yoshida Y. Miyazaki M. Shiiki H. Kohno S. Dohi K. expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. [Journal Article] American Journal of Kidney Diseases. 39(4): 695-705, 2002 April
**	٧	Thogersen AM. Jansson JH. Boman K. Nilsson TK. Weinehall L. Huhtasaari F. Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinalytic system as an independent primary risk factor. Liournal Article Circulation. 98(21): 2241-7, 1998 Nov. 24
*:	w	Takanashi K. Inukai T. Insulin resistance and changes in the blood coagulation-fibrinolysis system after a glucose clamp technique in patients with type 2 diabetes mellitus. [Journal Article] Journal of Medicine.31(1-2):45-62, 2000.
<b>:</b> >:	х	Takazoe K. Ogawa H. Yasue H. Sakamoto T. Soejima H. Miyao Y. Kawano H. Moriyama Y. Misumi K. Suefuji H. Kugiyama K. Yoshimura M. Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris, [Journal Arkie] Annals of Medicine. 33(3): 206-12, 2001 Apr.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Application/Control No. 10/731,074	Reexaminati	Applicant(s)/Patent Under Reexamination ELOKDAH ET AL.		
Examiner	Art Unit			
Michael P. Barker	1626	Page 3 of 5		

## U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-		·	
	D	US-			
	E	US-			
	F	US-		·	
	G	US-			
	н	US-			
	1	US-			
	J	US-			
	к	US-			
	L	US-			
	м	US-			

## FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N			•	· · · · · · · · · · · · · · · · · · ·	
	0					
	Р					
	Q					
-	R	·				
	S					,
	Т					

## NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
·x·	U	Mari D. Parnetti L. Coppola R. Bottasso B. Reboldi GP. Senin U. Mannucci PM. Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. [Journal Article] Thrombosis & Haemostasis. 75(2):216-8, 1996 Feb.
<b>&gt;</b>	v	Hino H. Akiyama H. Iseki E. Kato M. Kondo H. Ikeda K. Kosaka K. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues. [Journal Article] Neuroscience Letters. 297(2):105-8, 2001 Jan 12.
35	w	Atiomo WU. Hilton D. Fox R. Lee D. Shaw S. Friend J. Wilkin TJ. Prentice AG. Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries. [Journal Article] Gynecological Endocrinology. 14(3):162-8, 2000 Jun.
*	x	Glueck CJ. Phillips H. Cameron D. Sieve-Smith L. Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. [Clinical Trial. Journal Article] Fertility: 75(1): 46-52, 2001 Jan.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Application/Control No. 10/731,074	Applicant(s)/Pa Reexamination ELOKDAH ET	
Examiner	Art Unit	
Michael P. Barker	1626	Page 4 of 5

## **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Ε	US-			
	F	US-			
	G	US-			
	Н	US-			
	-	US-			
	J	US-			
	ĸ	US-			
	L	US-			
	М	US-			

## FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0				·	
	Р					
	Q					•
-	R					
	S					
	Т					

## NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
ν.	U	Billgren AM. Rutqvist LE. Johansson H. Hagerstrom T. Skoog L. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen. [Journal Article] European Journal of Cancer. 36 (11): 1374-80, 2000 Jul.
.* ·	٧	Wind T. Jensen MA. Andreasen PA. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding. [Journal Article] European Journal of Biochemistry. 268(4): 1095-106, 2001 Feb.
٠	w	Berry CN. Lunven C. Lechaire I. Girardot C. O'Connor SE. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. [Journal Article] British Journal of Pharmacology. 125 (1): 29-34, 1998 Sept.
٠.	х	Lahlou A. Peraldi MN. Thervet E. Flahault A. Delarue F. Soubrier F. Rossert J. Hertig A. Rondeau E. Chronic graft dysfunction in renal transplant patients: potential role of plasminogen activator inhibitor type 1. [Journal Article] Transplantation. 73(8):1290-5, 2002 Apr 24.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Application/Control No.

10/731,074

Examiner

Michael P. Barker

Applicant(s)/Patent Under
Reexamination
ELOKDAH ET AL.

Art Unit
Page 5 of 5

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	I	US-			
	J	US-			
	K	US-		·	
	L	US-			
	М	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R				·	
	s					
	Т	· · · · · · · · · · · · · · · · · · ·				

## NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)				
	U	Sobel BE. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. [Editorial] Proceedings of the Association of American Physicians. 111(4):313-8, 1999 Jul-Aug.				
,t	٧	Roldan V. Marin F. Marco P. Martinez JG. Calatayud R. Sogorb F. Hypofibrinolysis in atrial fibrillation. [Journal Article] American Heart Journal. 136(6):956-60, 1998 Dec.				
	w					
	х					

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Notice of References Cited

se state or has the note. I see that he was a see that

Part of Paper No. 20051024